...BRCA1 and BRCA2 genes. By analyzing 162 unique cited publications supporting VUS reclassifications, we examined the accu...
...BRCA1, treatment significantly alleviate SiNPs-stimulated down-regulation on expressions of BRCA1 and GPX4. Our findings...
...BRCA1 (1%; 95% CI: 1%-3%), BRCA2 (1%; 95% CI: 1%-3%), and TP53 (1%; 95% CI: 0%-3%). Patients with P/LP variants in DNA d...
...BRCA1/2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olapa...
Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment landscape for patients suffering from ...
...BRCA1/2 mutations. In our previous study, we found that CX-5461 inhibited GSH synthesis and promote lipid peroxidation i...
...BRCA1 gene in primates and mutational dynamics in viral sequences from the recent mpox epidemic. Our novel algorithm enh...
...BRCA1 and BRCA2 genes. Additional genes with a significant influence on cancer risk were selected for genetic panel scre...
...BRCA1 and PALB2, who achieved PR lasting approximately 7 months following salvage treatment with olaparib. We considered...
...BRCA1/2 mutation carriers (gBRCA1/2m) vs non-carriers (gBRCA1/2wt). Secondary objectives included differences in MDBB an...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269